DK3354263T3 - Tørpulverformuleringer - Google Patents

Tørpulverformuleringer Download PDF

Info

Publication number
DK3354263T3
DK3354263T3 DK18157741.2T DK18157741T DK3354263T3 DK 3354263 T3 DK3354263 T3 DK 3354263T3 DK 18157741 T DK18157741 T DK 18157741T DK 3354263 T3 DK3354263 T3 DK 3354263T3
Authority
DK
Denmark
Prior art keywords
dry powder
powder formulations
formulations
dry
powder
Prior art date
Application number
DK18157741.2T
Other languages
English (en)
Inventor
Rudi Mueller-Walz
Roland Steiner
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29726600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3354263(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jagotec Ag filed Critical Jagotec Ag
Application granted granted Critical
Publication of DK3354263T3 publication Critical patent/DK3354263T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Seasonings (AREA)
DK18157741.2T 2003-11-14 2004-11-04 Tørpulverformuleringer DK3354263T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0326632.7A GB0326632D0 (en) 2003-11-14 2003-11-14 Dry powder formulations
EP17187255.9A EP3275435A1 (en) 2003-11-14 2004-11-04 Dry powder formulations

Publications (1)

Publication Number Publication Date
DK3354263T3 true DK3354263T3 (da) 2022-11-14

Family

ID=29726600

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18157741.2T DK3354263T3 (da) 2003-11-14 2004-11-04 Tørpulverformuleringer
DK04798927.2T DK1689360T3 (da) 2003-11-14 2004-11-04 Tørpulverformuleringer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04798927.2T DK1689360T3 (da) 2003-11-14 2004-11-04 Tørpulverformuleringer

Country Status (17)

Country Link
US (5) US20070071690A1 (da)
EP (3) EP3354263B1 (da)
JP (1) JP4991304B2 (da)
CN (2) CN1878537B (da)
AU (1) AU2004288644B2 (da)
CA (1) CA2542450C (da)
CY (1) CY1119350T1 (da)
DK (2) DK3354263T3 (da)
ES (2) ES2929899T3 (da)
FI (1) FI3354263T3 (da)
GB (1) GB0326632D0 (da)
HK (1) HK1201447A1 (da)
HU (2) HUE060507T2 (da)
PL (2) PL3354263T3 (da)
PT (2) PT1689360T (da)
SI (2) SI3354263T1 (da)
WO (1) WO2005046636A1 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
GB0525254D0 (en) * 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
AU2012200449B2 (en) * 2005-12-21 2013-07-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE4 inhibitor and antileukotriene for the treatment of inflammatory diseases
EP1803457A1 (en) * 2005-12-30 2007-07-04 Krka Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition containing montelukast
EA021960B1 (ru) * 2005-12-30 2015-10-30 Крка, Товарна Здравил, Д.Д., Ново Место Таблетка, содержащая фармацевтически приемлемую соль монтелукаста в аморфной форме, и способ ее получения
GB0602897D0 (en) * 2006-02-13 2006-03-22 Jagotec Ag Improvements In Or Relating To Dry Powder Inhaler Devices
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
GB0625303D0 (en) * 2006-12-19 2007-01-24 Jagotec Ag Improvements in and relating to metered dose inhalers
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP2400950B1 (en) 2009-02-26 2019-05-22 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
AU2011287711B2 (en) * 2010-08-03 2016-10-27 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising a phosphodiesterase inhibitor
EP2608769B1 (en) * 2010-08-23 2019-11-06 Fraunhofer Gesellschaft zur Förderung der Angewand Humidified particles comprising a therapeutically active substance
AU2011308865B2 (en) 2010-09-29 2017-01-05 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
US10130800B2 (en) 2012-01-27 2018-11-20 Invisiderm, Llc Method of producing substances with supersaturated gas, transdermal delivery device thereof, and uses thereof
CN104487075A (zh) * 2012-02-29 2015-04-01 普马特里克斯公司 可吸入干粉剂
ES2600705T3 (es) 2012-03-13 2017-02-10 Respivert Limited Inhibidores de PI3 cinasa cristalinos
EP2836204B1 (en) 2012-04-13 2020-07-08 GlaxoSmithKline Intellectual Property Development Limited Aggregate particles
KR20130140358A (ko) 2012-06-14 2013-12-24 한미약품 주식회사 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
RU2686101C2 (ru) 2013-03-12 2019-04-24 Селтакссис, Инк. Способы ингибирования лейкотриен- а4-гидролазы
BR112015022226A2 (pt) 2013-03-14 2017-07-18 Celtaxsys Inc inibidores de leucotrieno a4 hidrolase
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
EP3060205A4 (en) * 2013-10-22 2017-06-28 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP3082428A4 (en) * 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CN105412049B (zh) * 2014-09-16 2020-01-07 四川海思科制药有限公司 一种干粉吸入剂用药物组合物及其制备方法
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
KR20180023884A (ko) 2015-01-07 2018-03-07 트라이제미나 인코퍼레이티드 마그네슘-함유 옥시토신 제제 및 사용 방법
JP6168258B1 (ja) * 2015-09-25 2017-07-26 株式会社村田製作所 アンテナモジュールおよび電子機器
TWI745396B (zh) 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
CA3033079A1 (en) 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
US11786460B2 (en) 2018-04-16 2023-10-17 Ioulia Tseti Pharmaceutical dry powder composition for inhalation comprising a thyroid hormone
US10898484B2 (en) 2018-05-31 2021-01-26 Celltaxis, Llc Method of reducing pulmonary exacerbations in respiratory disease patients
CN110856713B (zh) * 2018-08-23 2021-08-24 山东大学齐鲁医院 一种便携式治疗急性心衰发作的吸入式药物
JP2021536467A (ja) 2018-09-06 2021-12-27 インノファーマスクリーン インコーポレイテッド 喘息またはパーキンソン病の処置のための方法および組成物
CN109745565B (zh) * 2019-01-28 2021-05-18 上海方予健康医药科技有限公司 一种用于吸入的干粉组合物及其制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US175214A (en) * 1876-03-21 Elastic fluid turbine
DD98022A1 (da) 1972-06-30 1973-06-12
JPS528375B2 (da) 1973-07-02 1977-03-09
AT347054B (de) 1973-09-29 1978-12-11 Takeda Chemical Industries Ltd Verfahren zur herstellung von neuen nonapeptidamid-derivaten
GB1542703A (en) 1975-10-29 1979-03-21 Parke Davis & Co Nonapeptides and methods for their production
JPS5944308B2 (ja) 1976-03-23 1984-10-29 武田薬品工業株式会社 ペプタイド
US4124577A (en) 1977-06-13 1978-11-07 Warner-Lambert Nonapeptides and methods for their production
US4317815A (en) 1979-06-13 1982-03-02 Coy David Howard LH-RH Antagonists
US4672108A (en) 1981-12-07 1987-06-09 Hoffmann-La Roche Inc. Crystalline human leukocyte interferon
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB8622090D0 (en) 1986-09-12 1986-10-22 Wellcome Found Pharmacologically active compounds
US5110904A (en) 1989-08-07 1992-05-05 Abbott Laboratories Lhrh analogs
JP2861267B2 (ja) 1989-06-01 1999-02-24 萬有製薬株式会社 生理活性物質ｂｅ―１８２５７類
GB8919726D0 (en) 1989-08-31 1989-10-11 Fujisawa Pharmaceutical Co Ws7338 substances and preparation thereof
CA2032559C (en) 1989-12-28 2001-11-06 Kiyofumi Ishikawa Endothelin antagonistic cyclic pentapeptides
US5284828A (en) 1990-05-14 1994-02-08 Fujisawa Pharmaceutical Co. Ltd. Peptide compound and its preparation
CA2059380A1 (en) 1991-01-24 1992-07-25 Yiu-Kuen T. Lam Endothelin receptor antagonists isolated from microbispora
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
DE69220861T2 (de) 1991-08-13 1997-11-20 Takeda Chemical Industries Ltd Zyklische Peptide und ihre Verwendung
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
PT1568772E (pt) 1995-09-21 2010-04-14 Genentech Inc Variantes da hormona do crescimento humana
EP0865302B1 (de) 1995-12-07 2000-05-31 Jago Pharma Ag Inhalator zur mehrfachen dosisweisen abgabe eines pharmakologischen trockenpulvers
NL1006774C2 (nl) * 1996-08-14 1998-09-28 Univ Potchefstroom Anti-atherosclerose- en anti-trombotisch middel en het gebruik daarvan.
GB9806462D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Improved compositions for inhalation
EP1862164A3 (de) * 1998-11-13 2012-12-26 Jagotec AG Trockenpulver zur Inhalation
US20070212422A1 (en) 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
DK1158958T3 (da) 1999-03-05 2007-10-08 Chiesi Farma Spa Forbedret pulverformulering til inhalering
EP1129705A1 (en) 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Powder formulation for inhalation
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
WO2002007705A1 (en) 2000-07-20 2002-01-31 Campina B.V. Carrier material for dry powder inhalation
JP4125512B2 (ja) 2000-11-29 2008-07-30 伊藤ハム株式会社 粉末製剤及びその製造方法
EP1617820B1 (en) 2003-04-14 2018-03-21 Vectura Limited Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds

Also Published As

Publication number Publication date
CY1119350T1 (el) 2018-02-14
US20130014758A1 (en) 2013-01-17
EP3275435A1 (en) 2018-01-31
PL1689360T3 (pl) 2017-11-30
US20100028269A1 (en) 2010-02-04
HUE034450T2 (en) 2018-02-28
SI3354263T1 (sl) 2023-04-28
EP1689360A1 (en) 2006-08-16
GB0326632D0 (en) 2003-12-17
AU2004288644B2 (en) 2011-05-12
CA2542450A1 (en) 2005-05-26
ES2645442T3 (es) 2017-12-05
PL3354263T3 (pl) 2023-01-23
US8246935B2 (en) 2012-08-21
WO2005046636A1 (en) 2005-05-26
EP3354263B1 (en) 2022-08-10
PT3354263T (pt) 2022-11-11
FI3354263T3 (fi) 2022-11-30
PT1689360T (pt) 2017-09-22
HK1201447A1 (en) 2015-09-04
EP1689360B1 (en) 2017-08-23
SI1689360T1 (sl) 2017-12-29
CN1878537A (zh) 2006-12-13
US20120107406A1 (en) 2012-05-03
HUE060507T2 (hu) 2023-03-28
US20100035854A1 (en) 2010-02-11
EP3354263A1 (en) 2018-08-01
JP2007511502A (ja) 2007-05-10
JP4991304B2 (ja) 2012-08-01
CN1878537B (zh) 2014-08-20
US20070071690A1 (en) 2007-03-29
ES2929899T3 (es) 2022-12-02
DK1689360T3 (da) 2017-11-13
CN104224720A (zh) 2014-12-24
AU2004288644A1 (en) 2005-05-26
US8211405B2 (en) 2012-07-03
CA2542450C (en) 2013-08-13
US8414867B2 (en) 2013-04-09

Similar Documents

Publication Publication Date Title
DK3354263T3 (da) Tørpulverformuleringer
NO20035251D0 (no) Törrpulverinhalator
IS8309A (is) Lyfjablöndur
DK3494995T3 (da) Superfin formoterolformulering
DE502004001401D1 (de) Zyklonabscheider
FR2842417B1 (fr) Composition cosmetique
DK1812025T3 (da) Stabiliserede bakteriofagformuleringer
FR2842416B1 (fr) Composition cosmetique
PT1501534E (pt) Formulacoes farmaceuticas
DE602004011856D1 (de) Kosmetik
DE60307595D1 (de) Schminkdose
DE602005012016D1 (de) Kosmetischer komprimierter Puder
FR2862654B1 (fr) Composition amylacee filmogene
NO20043418L (no) Stabiliserte adenovirusformuleringer
ATE352301T1 (de) Antineoplastische zusammensetzungen
DE502004004375D1 (de) Wäschetrockner
DE60310914D1 (de) Pulverzusammensetzung
IS7501A (is) thurrdufts innöndunar samsetning
DK1539089T3 (da) Reducerede aerosol-genererende formuleringer
IS7500A (is) thurrdufts samsetningar
DE60221611D1 (de) Trockenpulverinhalator
DE602004004388D1 (de) Verdickbare zusammensetzungen
IS7582A (is) Hraðlosandi lyfjablanda
DE602004004266D1 (de) Pulverspender
GB0307765D0 (en) Tissue-adhesive formulations